id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-348249-zhfrgaxf	Osborne, V.	Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making	2020-05-12		.txt	text/plain	3919	226	49	Methods: The overall benefit-risk of the use of chloroquine or hydroxychloroquine as a treatment for COVID-19 compared to standard of care, placebo or other treatments was assessed using the Benefit-Risk Action Team (BRAT) framework. To date, whilst there have been many publications which have described the main effectiveness and safety concerns with these treatments, there has not been a systematic benefit-risk assessment on the use of chloroquine or hydroxychloroquine for COVID-19 treatment using a structured descriptive framework. To examine the benefit-risk profile of chloroquine or hydroxychloroquine in COVID-19 patients compared to standard of care, placebo or other treatments. The overall benefit-risk of the use of chloroquine or hydroxychloroquine as a treatment for COVID-19 compared to standard of care, placebo or other treatments was assessed using the BRAT framework. Data were extracted for each benefit and risk, for hydroxychloroquine, chloroquine and the comparator (standard of care, placebo or other treatments), where available.	./cache/cord-348249-zhfrgaxf.txt	./txt/cord-348249-zhfrgaxf.txt